🇺🇸 FDA
Patent

US 11648247

Compositions and methods for the treatment of presbyopia

granted A61KA61K31/439A61K31/498

Quick answer

US patent 11648247 (Compositions and methods for the treatment of presbyopia) held by Lenz Therapeutics, Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lenz Therapeutics, Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/439, A61K31/498, A61K47/02, A61K47/10